about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionPredicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical ModelsPharmacokinetic drug interactions in liver disease: An updateEvaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOC(TM)) SystemMetrabase: a cheminformatics and bioinformatics database for small molecule transporter data analysis and (Q)SAR modelingRole of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitorsSystems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cellsCytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.Renal handling of amphotericin B and amphotericin B-deoxycholate and potential renal drug-drug interactions with selected antivirals.Quantitative structure-pharmacokinetic relationships for the prediction of renal clearance in humansBiochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance proteinClinically significant psychotropic drug-drug interactions in the primary care setting.Expression of drug transporters in human kidney: impact of sex, age, and ethnicity.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study.Prediction of drug-induced nephrotoxicity and injury mechanisms with human induced pluripotent stem cell-derived cells and machine learning methods.Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies.Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.Breast cancer resistance protein (Bcrp) and the testis--an unexpected turn of events.SLCO1B1 variants and urine arsenic metabolites in the Strong Heart Family Study.Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapyAbsolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure.Pharmacological potential of biogenic amine-polyamine interactions beyond neurotransmission.Nuclear receptors in regulation of biotransformation enzymes and drug transporters in the placental barrier.Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.Biomarkers and human hepatocytes.Extrahepatic metabolism at the body's internal-external interfaces.Antiviral drug discovery: broad-spectrum drugs from nature.Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms.Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies.Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.Human transporters, PEPT1/2, facilitate melatonin transportation into mitochondria of cancer cells: An implication of the therapeutic potential.Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1.Influence of drug formulation on OATP1B-mediated transport of paclitaxel.Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP.Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactionsMechanistic models describing active renal reabsorption and secretion: a simulation-based study.Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin
P2860
Q24273350-E01D178C-C088-4610-B71B-0390EDFB205AQ26764739-EA65CCC3-A685-433C-9863-5CCA62BD4E21Q26774479-3DF92498-BE6D-43EF-B609-E83E6426CB4AQ26801904-9E124D64-7DB3-4019-A96B-79DCFD3B2BA0Q27902340-CCA82D01-DE9F-472E-88FF-4B2027727D34Q28236180-D00CE390-36DB-4656-B234-E4C6B9D9B2F7Q30833363-F7AA9399-A746-4F46-BBC0-5BE7CC040489Q33887999-E73222D4-4132-4358-8225-9E2713E9BC2AQ34298854-E9DEA7E2-048C-4140-83F7-8C2AD31142A6Q34785494-7F89C27A-4039-41F9-B8CB-8947143AFFC2Q35033091-F99DD1CA-F484-4926-93E0-D0B59F7A2F26Q35104220-2C0B8983-2FB6-4C3D-A8D2-ED297F47D823Q35155504-6B023314-6F22-4A46-B9DB-ED376475165EQ35708124-7C93506C-4B17-4F10-8E81-476B3A9D5030Q35802617-D868FE2E-194A-440E-B485-2C1F4FF3D94BQ35891133-DC481588-A5F5-4126-926E-9794DA010208Q36306228-CA9207B6-C853-4CDF-8CA1-61A96E2362E8Q36362462-F76418D1-4309-427A-AA05-3A9F38A233BCQ36935249-EC453BDD-5FD6-47B9-A5B8-9F27DC09EA62Q37084405-4E46DF8F-D014-4504-96A0-A32E6C5A7D44Q37312651-E2FE0D91-89A5-4526-A524-F427850A7004Q37735146-F3F9315C-978D-4BE4-A07A-2E810C8B6F8BQ38038547-7877BAA4-A093-4E3F-B9D7-4E41E20FB26BQ38044958-7C934B9B-4CF6-4915-8657-D735863165B0Q38076471-7D033B17-AB1B-4435-B336-A6B7DBD08C30Q38135859-F128938F-85CF-4DF3-BB70-643F056CD43AQ38175870-E2361758-AFEF-4190-9DE7-6E6811A37C23Q38187449-46E41FF7-C5E7-4201-A266-6365141C8A95Q38199198-EAFCEE9C-D1DA-49E3-A30F-BBA063B8B4D8Q38260235-91BAFF85-CDDD-4F35-9B1D-0CDA8E1876ACQ38336214-B2D7BA8F-A6B4-4749-A913-FF0B7397A80DQ38511370-03C51992-E139-44C0-92B4-8D25642177F7Q38581826-FD76FCC8-AB75-4CA4-9A3A-E17D530C632EQ38720727-6F1FD36C-E6FB-4631-9B74-A0E496878D77Q38844650-DADDAB02-1763-47BE-8E16-D2E776FB8824Q39001980-363FF096-7405-4456-B1D6-9B9694EC1BEEQ39233839-F1BA99F8-F208-4626-B45F-92D96D8F78E3Q41620033-458056A5-B901-4507-90F6-74ECEFC8A3EFQ41986968-E5620B14-269F-4D2F-A7C1-A32CEF0E09F3Q42092470-74AC6DCD-01E8-4001-B9EF-DD3C5673CCAF
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Transporter-mediated drug-drug interactions.
@en
Transporter-mediated drug-drug interactions.
@nl
type
label
Transporter-mediated drug-drug interactions.
@en
Transporter-mediated drug-drug interactions.
@nl
prefLabel
Transporter-mediated drug-drug interactions.
@en
Transporter-mediated drug-drug interactions.
@nl
P2860
P356
P1433
P1476
Transporter-mediated drug-drug interactions.
@en
P2093
Fabian Müller
Martin F Fromm
P2860
P304
P356
10.2217/PGS.11.44
P577
2011-07-01T00:00:00Z